Press release
Eosinophilic Gastroenteritis Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight
Eosinophilic Gastroenteritis Treatment Market
(Albany, USA) DelveInsight's "Eosinophilic Gastroenteritis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Eosinophilic Gastroenteritis, historical and forecasted epidemiology as well as the Eosinophilic Gastroenteritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Some of the key facts of the Eosinophilic Gastroenteritis Market Report:
* The Eosinophilic Gastroenteritis market size was valued approximately USD 78 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
* More than 31,000 cases of Eosinophilic Gastroenteritis were reported in the US in 2021, but only about 2,800 cases were reported in Spain
* In the United States in 2021, there were approximately 16,500 males and 15,000 females who had eosinophilic gastroenteritis. By 2032, the prevalence is anticipated to rise
* In 2021, Germany had the most common incidence of eosinophilic gastroenteritis among the EU5 nations (about 4,400 cases)
* Key Eosinophilic Gastroenteritis Companies: Allakos, AstraZeneca, Invea Therapeutics, Pfizer, Ception Therapeutics, Regeneron, EsoCap AG, Celgene, Allakos Inc., Ellodi Pharma, Takeda, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Novartis, EMS, Celgene, Oxagen Ltd, and others
* Key Eosinophilic Gastroenteritis Therapies: Lirentelimab, Benralizumab, INVA8001, Etrasimod, reslizumab, Dupilumab, ESO-101, CC-93538, AK002, APT-1011, budesonide, Mesalamine, IRL201104, QAX576, Florence 30 g/mL, RPC4046, OC000459, and others
* The Eosinophilic Gastroenteritis epidemiology based on gender analyzed that Eosinophilic Gastroenteritis shows slight predominance in males than females in the US. However, in eosinophilic esophagitis (EoE), there is no male predominance
* The Eosinophilic Gastroenteritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Eosinophilic Gastroenteritis pipeline products will significantly revolutionize the Eosinophilic Gastroenteritis market dynamics.
* In December 2024, Astrazeneca announced results of a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).
* In October 2024, Regeneron Pharmaceuticals announced a Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
To Know in detail about the Eosinophilic Gastroenteritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Eosinophilic Gastroenteritis Market Forecast [https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Eosinophilic Gastroenteritis Overview
Eosinophilic gastroenteritis (EGE) is a rare, chronic inflammatory condition characterized by an abnormal accumulation of eosinophils, a type of white blood cell, in the gastrointestinal (GI) tract. This disorder can affect any part of the GI tract, from the esophagus to the colon, and its symptoms vary depending on the location and depth of eosinophil infiltration. Common symptoms include abdominal pain, nausea, vomiting, diarrhea, weight loss, and in severe cases, intestinal obstruction or perforation. Eosinophilic Gastroenteritis is thought to result from an abnormal immune response, often associated with food allergies, environmental allergens, or other atopic conditions like asthma or eczema. The diagnosis of Eosinophilic Gastroenteritis typically involves a combination of clinical evaluation, endoscopic procedures, and biopsy, which reveal elevated eosinophil counts in the GI tissue.
Management of Eosinophilic Gastroenteritis primarily focuses on reducing inflammation and controlling symptoms. Dietary modifications, such as elimination diets to identify and avoid triggering foods, are often the first line of treatment. Pharmacological therapies include corticosteroids to reduce inflammation and immunomodulators to control the immune response. In some cases, biologic agents targeting specific pathways involved in eosinophil activation and recruitment may be used.
Despite its chronic nature, ongoing research into the pathophysiology of Eosinophilic Gastroenteritis and advancements in targeted therapies offer hope for improved management and outcomes for patients with this challenging condition.
Get a Free sample for the Eosinophilic Gastroenteritis Market Report: https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market [https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Eosinophilic Gastroenteritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Eosinophilic Gastroenteritis Epidemiology Segmentation:
The Eosinophilic Gastroenteritis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
* Total Prevalence of Eosinophilic Gastroenteritis
* Prevalent Cases of Eosinophilic Gastroenteritis by severity
* Gender-specific Prevalence of Eosinophilic Gastroenteritis
* Diagnosed Cases of Episodic and Chronic Eosinophilic Gastroenteritis
Download the report to understand which factors are driving Eosinophilic Gastroenteritis epidemiology trends @ Eosinophilic Gastroenteritis Epidemiology Forecast [https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Eosinophilic Gastroenteritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Eosinophilic Gastroenteritis market or expected to get launched during the study period. The analysis covers Eosinophilic Gastroenteritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Eosinophilic Gastroenteritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Eosinophilic Gastroenteritis Therapies and Key Companies
* Lirentelimab: Allakos
* Benralizumab: AstraZeneca
* INVA8001: Invea Therapeutics
* Etrasimod: Pfizer
* reslizumab: Ception Therapeutics
* Dupilumab: Regeneron
* ESO-101: EsoCap AG
* CC-93538: Celgene
* AK002: Allakos Inc.
* APT-1011: Ellodi Pharma
* budesonide: Takeda
* Mesalamine: Dr. Falk Pharma GmbH
* IRL201104: Revolo Biotherapeutics
* QAX576: Novartis
* Florence 30 g/mL: EMS
* RPC4046: Celgene
* OC000459: Oxagen Ltd
Discover more about therapies set to grab major Eosinophilic Gastroenteritis market share @ Eosinophilic Gastroenteritis Treatment Market [https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Eosinophilic Gastroenteritis Market Drivers
* Increasing disease burden due to increasing prevalence in the general population
* A better understanding of disease pathogenesis may lead to the identification of novel molecular targets for the treatment
Eosinophilic Gastroenteritis Market Barriers
* Lack of approved therapies indicated for EGE in the US, EU, and Japan
* Huge annual psychological, social, and economic burden (QALY), in advanced countries, due to EGE
Scope of the Eosinophilic Gastroenteritis Market Report
* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Eosinophilic Gastroenteritis Companies: Allakos, AstraZeneca, Invea Therapeutics, Pfizer, Ception Therapeutics, Regeneron, EsoCap AG, Celgene, Allakos Inc., Ellodi Pharma, Takeda, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Novartis, EMS, Celgene, Oxagen Ltd, and others
* Key Eosinophilic Gastroenteritis Therapies: Lirentelimab, Benralizumab, INVA8001, Etrasimod, reslizumab, Dupilumab, ESO-101, CC-93538, AK002, APT-1011, budesonide, Mesalamine, IRL201104, QAX576, Florence 30 g/mL, RPC4046, OC000459, and others
* Eosinophilic Gastroenteritis Therapeutic Assessment: Eosinophilic Gastroenteritis current marketed and Eosinophilic Gastroenteritis emerging therapies
* Eosinophilic Gastroenteritis Market Dynamics: Eosinophilic Gastroenteritis market drivers and Eosinophilic Gastroenteritis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Eosinophilic Gastroenteritis Unmet Needs, KOL's views, Analyst's views, Eosinophilic Gastroenteritis Market Access and Reimbursement
To know more about Eosinophilic Gastroenteritis companies working in the treatment market, visit @ Eosinophilic Gastroenteritis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Eosinophilic Gastroenteritis Market Report Introduction
2. Executive Summary for Eosinophilic Gastroenteritis
3. SWOT analysis of Eosinophilic Gastroenteritis
4. Eosinophilic Gastroenteritis Patient Share (%) Overview at a Glance
5. Eosinophilic Gastroenteritis Market Overview at a Glance
6. Eosinophilic Gastroenteritis Disease Background and Overview
7. Eosinophilic Gastroenteritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Eosinophilic Gastroenteritis
9. Eosinophilic Gastroenteritis Current Treatment and Medical Practices
10. Eosinophilic Gastroenteritis Unmet Needs
11. Eosinophilic Gastroenteritis Emerging Therapies
12. Eosinophilic Gastroenteritis Market Outlook
13. Country-Wise Eosinophilic Gastroenteritis Market Analysis (2019-2032)
14. Eosinophilic Gastroenteritis Market Access and Reimbursement of Therapies
15. Eosinophilic Gastroenteritis Market Drivers
16. Eosinophilic Gastroenteritis Market Barriers
17. Eosinophilic Gastroenteritis Appendix
18. Eosinophilic Gastroenteritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eosinophilic-gastroenteritis-treatment-market-2032-ema-pdma-fda-approvals-clinical-trials-therapies-epidemiology-medication-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Eosinophilic Gastroenteritis Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight here
News-ID: 3802937 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Eosinophilic
Eosinophilic Esophagitis Market to Surge to USD 4.1 Billion by 2034
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus, characterized by eosinophil infiltration, difficulty swallowing, food impaction, and chest pain. Once considered rare, EoE has now emerged as one of the most common causes of dysphagia in children and adults, particularly in developed nations. Strong associations with allergic conditions such as asthma, eczema, and food allergies underscore its complex immunological nature.
Download Full PDF Sample Copy of Market…
Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2030
The eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
Severe Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2 …
The severe eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines…
Eosinophilic Esophagitis Pipeline, Clinical Trials Assessment, Emerging Therapie …
DelveInsight's, "Eosinophilic Esophagitis Pipeline Insight" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Eosinophilic Esophagitis research. Learn more about…
Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Analysis …
According to our (Global Info Research) latest study, the global Eosinophilic Granulomatosis with Polyangiitis Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Eosinophilic Granulomatosis with…
Eosinophilic Granulomatosis Treatment Market Size and Overview Upto 2028|
 The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Eosinophilic Granulomatosis Treatment market. It includes Porter's Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Eosinophilic Granulomatosis Treatment Market. We have provided a deep analysis of the vendor landscape to give…
